L&K BIOMED LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,330 KRW | +2.19% |
|
-0.74% | -8.35% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -8.35% | 138M | - | ||
| +11.21% | 127B | A- | ||
| -4.91% | 11.32B | A- | ||
| +3.22% | 9.04B | C | ||
| +38.81% | 5.56B | B+ | ||
| -23.27% | 4.72B | C | ||
| +8.44% | 3.45B | C- | ||
| -7.46% | 2.86B | B- | ||
| -6.99% | 2.07B | - | ||
| -13.32% | 2.04B | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- A156100 Stock
- Ratings L&K Biomed Ltd.
